Genentech Xolair Covered Under Patent License, PDL Says; Seeks Royalties
Executive Summary
Protein Design Labs is seeking lower-level staff discussions with Genentech to determine whether the humanized anti-IgE antibody Xolair requires a license under PDL's antibody humanization patents
You may also be interested in...
Genentech Xolair Average Cost Is $10,000 A Year; Mid-July Launch Planned
Genentech/Novartis' allergic asthma treatment Xolair will cost about $10,000 a year for the average patient at mid-July launch
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials